ORM-5029

N/A

Report date: 2025/05/07 17:31:15

Base Information

Drug NameORM-5029

Drug Alias NameORM-5029

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > SMol006 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionEukaryotic peptide chain release factor GTP-binding subunit ERF3A degradersReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsEukaryotic peptide chain release factor GTP-binding subunit ERF3AReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsSolid tumoursBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesOrum Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesOrum Therapeutics Inc

Active IndicationsN/A

Inactive IndicationsSolid tumoursBreast Neoplasms

Other Information

ATC CodeN/A